Twist Bioscience (NASDAQ:TWST – Get Rating) had its price objective reduced by Robert W. Baird from $56.00 to $33.00 in a research report sent to investors on Monday morning, The Fly reports. They currently have an outperform rating on the stock.
A number of other equities analysts have also recently issued reports on the company. SVB Leerink decreased their target price on Twist Bioscience from $45.00 to $30.00 and set a market perform rating on the stock in a report on Monday. Barclays decreased their target price on Twist Bioscience from $45.00 to $43.00 and set an overweight rating on the stock in a report on Monday.
Twist Bioscience Stock Up 1.3 %
Shares of NASDAQ TWST opened at $25.53 on Monday. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -6.33 and a beta of 1.15. The stock’s fifty day simple moving average is $32.37 and its 200 day simple moving average is $36.79. Twist Bioscience has a 52-week low of $23.90 and a 52-week high of $99.74.
Insider Transactions at Twist Bioscience
Institutional Trading of Twist Bioscience
Several hedge funds and other institutional investors have recently modified their holdings of the business. Capital Impact Advisors LLC boosted its position in shares of Twist Bioscience by 6.3% in the third quarter. Capital Impact Advisors LLC now owns 19,177 shares of the company’s stock worth $487,000 after buying an additional 1,132 shares during the period. Sandia Investment Management LP acquired a new stake in Twist Bioscience during the third quarter valued at $88,000. BNP Paribas Arbitrage SNC boosted its position in Twist Bioscience by 593.0% during the third quarter. BNP Paribas Arbitrage SNC now owns 89,246 shares of the company’s stock valued at $3,145,000 after purchasing an additional 76,367 shares during the last quarter. Thrivent Financial for Lutherans acquired a new stake in Twist Bioscience during the third quarter valued at $1,978,000. Finally, Two Sigma Investments LP acquired a new stake in Twist Bioscience during the third quarter valued at $2,995,000.
About Twist Bioscience
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.
- Get a free copy of the StockNews.com research report on Twist Bioscience (TWST)
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.